Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Metabolic Factors May Play a Role in Risk for Breast Cancer - (DGNews)
    TopAbstracts in Breast Cancer 06/30/2009 - (DGNews)
    Protein-Bound Paclitaxel Suspension Approved in Quebec for Metastatic Breast Cancer - (DGNews)
    TopAbstracts in Breast Cancer 06/23/2009 - (DGNews)
    TopAbstracts in Breast Cancer 06/16/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer
  • Optimizing the Use of Chemotherapy as the Backbone of Breast Cancer Treatment: An Update of the Latest Evidence
  • Applying Key Biomarkers in Oncology: From Biospecimen Preparation and Storage to Clinical Implications
  • Finding Ways to Prevent, Circumvent, or Overcome Cardiovascular Toxicity Associated With Modern Breast Cancer Therapies
  • Cutaneous Metastasis of Breast Carcinoma Presenting as Alopecia Neoplastica

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Bilateral Swollen Eyelids Occurring During Adjuvant Treatment with Tamoxifen for Early Breast Cancer
      Ruptured Gallbladder as the First Presentation of Breast Cancer
      Synchronous Infiltrating Ductal Carcinoma and Primary Extramedullary Plasmacytoma of the Breast
      Primary Anaplastic Large Cell Lymphoma of the Breast Arising in Reconstruction Mammoplasty Capsule of Saline Filled Breast Implant after Radical Mastectomy for Breast Cancer: An Unusual Case Presentation
      The Radiologic Workup of a Palpable Breast Mass

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Neoadjuvant Docetaxel Improves Survival in Breast Cancer Patients: Presented at SABCS

      By Charlene Laino

      SAN ANTONIO, TX -- December 4, 2003 -- Primary chemotherapy with docetaxel significantly improves 5-year survival rates of women with breast cancer compared with standard neoadjuvant chemotherapy, according to results of the University of Aberdeen trial.

      Andrew Hutcheon, MD, consultant medical oncologist, Grampian University Hospital Trust, Aberdeen, Scotland, United Kingdom, reported the findings here on December 3rd at the 26th Annual San Antonio Breast Cancer Symposium.

      The study enrolled 162 women with T3, T4, or N2 breast cancers; who received four courses of cyclophosphamide, doxorubicin, vincristine and prednisolone for 5 days. The 102 patients who responded were then randomized to receive either four more courses of the same drugs or four courses of docetaxel. The patients who failed to respond all received four cycles of docetaxel.

      At a median follow-up of 65 months, 5-year survival was 97% in the docetaxel arm and 78% in the anthracycline-based chemotherapy arm. This was significant at the P = .04 level, Dr. Hutcheon said.

      In addition, disease-free survival rates were 90% and 72% in the docetaxel and anthracycline-based chemotherapy arms, respectively (P = .04).

      The study also showed that patients who received neoadjuvant docetaxel had a higher complete pathological response rate -- 31% versus 15%, respectively (P = .06).

      "This [better pathological response rate] resulted in significantly more breast conserving surgery in the docetaxel arm," Dr. Hutcheon said. "Breast-conserving therapy was possible in 67% of women who received docetaxel, compared with 49% of those who received anthracycline-based chemotherapy."

      Docetaxel was better tolerated, with 48% of women developing neutropenia compared with 59% of those on conventional therapy, he said. Also, 60% and 69% of women, respectively, developed granulocytopenia. Both of these differences were statistically significant, Dr. Hutcheon said.


      [Study title: Docetaxel Primary Chemotherapy in Breast Cancer: A Five Year Update of the Aberdeen Trial. Abstract 11]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send